Efficacy of Natalizumab therapy in patients of African descent With RRMS
Summary
Patients of African descent often experience a more aggressive disease course, with more frequent relapses, faster progression to a secondary progressive stage, and less robust response to Beta-interferon. In this paper a post hoc analysis was performed on two pivotal trials of Natalizumab: AFFIRM and SENTINEL trials. Forty nine patients of African descent were evaluated.
It was found that Natalizumab therapy significantly reduced the relapse rate in this population, as well as T2 lesions and gadolinium-enhancing lesions on MRI. As there is limited information on people of African descent with MS this paper would support its use as a second line therapy for those with ongoing disease activity despite treatment with Beta-interferons or glatiramer acetate.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768
Natalizumab therapy in patients of African descent
Natalizumab therapy in patients of African descent
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2122 Views
-
Last post by frodo
-
- 0 Replies
- 1194 Views
-
Last post by NHE
-
- 0 Replies
- 1748 Views
-
Last post by Petr75
-
- 0 Replies
- 10355 Views
-
Last post by NHE
-
- 2 Replies
- 1839 Views
-
Last post by frodo
-
- 0 Replies
- 2529 Views
-
Last post by NHE
-
- 0 Replies
- 2469 Views
-
Last post by frodo
-
- 1 Replies
- 1832 Views
-
Last post by frodo
-
- 0 Replies
- 1411 Views
-
Last post by frodo